Denali Therapeutics Inc
Statements
Cash Flow
Denali Therapeutics Inc (DNLI) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -97 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21 | -18 | -19 | -18 | -22 | -18 | 34 | -42 | -35 | 93 | -30 | -43 | -30 | -48 | -54 | -43 | 0.1 | 514 | -50 | -54 | -41 | -65 | -72 | -43 | -57 | -73 | -59 | -113 | -87 | -99 | -114 | -91 | -59 | -84 | -131 | -75 | -107 | -99 | -131 | -97 | -434 | |
| 0.4 | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 1.9 | 2.3 | 2.4 | 2.4 | 1.6 | 1.9 | 2.1 | 2.1 | 2.1 | 2.2 | 1.4 | 1.4 | 1.5 | 1.4 | 1.3 | 1.3 | 1.2 | 1.3 | 3.2 | 10 | 1.4 | 2.2 | 2.2 | 2.2 | 1.9 | 1.8 | 1.9 | 3.2 | 3.0 | 2.9 | 3.8 | 3.8 | 2.7 | 13 | |
| 1.2 | 0.7 | 0.8 | 1.1 | 1.1 | 1.5 | 2.9 | 4.7 | 5.5 | 5.6 | 6.9 | 14 | 8.9 | 8.9 | 11 | 12 | 13 | 14 | 21 | 21 | 21 | 22 | 26 | 24 | 25 | 25 | 28 | 27 | 27 | 26 | 28 | 25 | 25 | 25 | 25 | 25 | 25 | 24 | 23 | 23 | 95 | |
| – | 8.5 | 1.3 | 1.3 | 1.3 | 5.2 | 2.9 | 4.7 | 5.5 | 5.6 | 6.9 | 13 | 8.8 | 6.5 | 11 | 12 | 13 | 14 | 21 | 23 | 21 | 24 | 26 | 24 | 25 | 21 | 28 | 27 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.6 | -0.6 | 0.8 | 2.3 | -2.2 | 2.4 | 54 | 7.0 | -6.5 | 8.5 | 0.7 | 1.5 | 6.4 | -2.2 | -9.6 | 2.5 | 44 | 253 | -3.8 | -19 | 18 | -16 | -36 | -9.8 | 21 | 0.7 | 22 | -313 | -4.4 | 5.8 | -16 | -8.2 | 30 | 11 | -22 | 23 | -6.2 | 5.0 | -27 | 4.3 | -24 | |
| 2.3 | 2.3 | 0.9 | 0.6 | 0.4 | 1.1 | 0.5 | 0.6 | 0.8 | 1.4 | 2.0 | 10 | 2.8 | 2.8 | 0.9 | 0.3 | 0.7 | 1.2 | 2.8 | 0.8 | 1.9 | 3.1 | 4.0 | 2.9 | 6.1 | 4.8 | 2.8 | 5.9 | 2.1 | 2.2 | 2.2 | 4.8 | 3.9 | 5.1 | 5.1 | 4.3 | 1.4 | 1.5 | 2.5 | 0.8 | 6.2 | |
| -149 | -19 | 15 | 22 | 17 | -41 | -301 | 31 | 45 | -61 | -8.0 | 64 | 49 | 42 | -13 | -30 | -212 | -367 | -25 | 98 | -53 | -41 | -118 | 89 | 15 | -128 | -93 | 168 | 101 | 73 | -453 | 99 | 94 | 172 | 19 | 158 | 58 | 21 | 94 | -104 | 69 | |
| – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0 | 0.2 | 0.2 | 0.4 | 266 | 93 | 1.4 | 0.7 | -93 | 0.9 | 2.6 | 0.7 | 6.2 | 196 | 3.4 | 5.8 | 9.5 | 3.8 | 7.0 | 3.3 | 5.2 | 1.5 | 4.4 | 5.2 | – | 1.6 | 9.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -24 | -8.3 | -4.4 | -2.4 | -1.4 | 0.0 | 0.0 | 0.0 | -1.4 | |
| 7.7 | 0.0 | 0.3 | 0.1 | 0.4 | 296 | 93 | 1.4 | 0.7 | 1.7 | 0.9 | 2.6 | 0.7 | 2.0 | 196 | 3.4 | 426 | 9.5 | 3.8 | 7.0 | 3.3 | 5.2 | 1.5 | 4.4 | 5.2 | 300 | 1.6 | 9.0 | 2.5 | 4.7 | 500 | 6.8 | -19 | -4.2 | -3.8 | 1.6 | -0.8 | 192 | 219 | 15 | 425 | |
| -163 | -37 | -3.1 | 4.6 | -5.6 | 182 | -174 | -9.9 | 11 | 33 | -37 | 23 | 20 | -3.2 | 128 | -70 | 214 | 156 | -72 | 50 | -91 | -101 | -189 | 50 | -36 | 99 | -150 | 64 | 16 | -21 | -67 | 14 | 16 | 84 | -116 | 84 | -50 | 114 | 182 | -186 | 60 | |
| -24 | -21 | -20 | -18 | -22 | -19 | 33 | -42 | -36 | 92 | -32 | -53 | -33 | -50 | -55 | -44 | -0.6 | 513 | -53 | -55 | -43 | -69 | -76 | -46 | -63 | -78 | -62 | -119 | -89 | -101 | -116 | -96 | -63 | -89 | -137 | -80 | -106 | -100 | -134 | -98 | -437 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.